We thank Drs Xia and Hua for their interest in our work [1]. The authors cite two retrospective studies with smaller numbers of patients than our prospective randomised trial and no control groups to suggest eplerenone may be of benefit in chronic central serous chorioretinopathy (CSCR) [2, 3]. When seeking funding for, and designing, our double-blind placebo-controlled trial, we also thought eplerenone was a plausible intervention based on previous pilot data. Unfortunately, in we found no evidence that it was of any benefit when we assessed the primary outcome of visual acuity or secondary structural outcomes [4].

They also question whether we could have missed choroidal neovascularisation as we did not screen patients with optical coherence tomography angiography. This technique was not widely available at the time of our study. However, no choroidal neovascularisation was seen in patients with fluorescein or indocyanine green angiography. We excluded patients older than 60 years to reduce the chance of including patients with choroidal neovascularisation. If any of these patients were included, these individuals would have been distributed randomly between the two groups so are very unlikely to have skewed our results.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD